Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Io Therapeutics, Inc.
RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models
August 5, 2026
Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention
April 29, 2026